Despite Navigating More Challenging Regulation Process Biotech Companies Thriving in 2012
July 24 2012 - 8:20AM
Marketwired
The Biotechnology Industry has been soaring in 2012 as companies --
both large and small -- have shown impressive growth. The SPDR
S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech
Index ETF (FBT) year-to-date are up 38 percent and 37 percent,
respectively, outperforming the broader market by a wide margin.
The Paragon Report examines investing opportunities in the
Biotechnology Industry and provides equity research on AEterna
Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) and MannKind Corporation
(NASDAQ: MNKD).
Access to the full company reports can be found at:
www.ParagonReport.com/AEZS www.ParagonReport.com/MNKD
Despite having to negotiate a more challenging regulation
process biotech companies have continued to show investors strong
gains in 2012. The FDA Amendments Act of 2007 forced regulators to
increase standards for approvals of new drugs, introducing
mandatory risk evaluation and mitigation strategies. According to a
Pharmaceuticals & Biotechnology report from IMAP, several
pharmaceutical firms have altered their drug portfolios from
primary care driven blockbusters towards specialties such as
oncology, immunology and inflammation, where the medical need is
"so high that prices are more easily accepted by the
regulators."
Paragon Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.ParagonReport.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. The company last month reported its Japanese
partner Yakult Honsha has initiated a Phase 1 trial in multiple
myeloma, a form of blood cancer, with perifosine.
MannKind is a biopharmaceutical company focused on the
discovery, development and commercialization of therapeutic
products for patients with diseases such as diabetes and cancer.
Their lead investigational product candidate, AFREZZA is a novel,
ultra rapid-acting mealtime insulin therapy. AFREZZA is in late
stage clinical investigation for the treatment of adults with type
1 or type 2 diabetes.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at: http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024